AUPN999096A0 - Peptides, antibodies, vaccines & uses thereof - Google Patents

Peptides, antibodies, vaccines & uses thereof

Info

Publication number
AUPN999096A0
AUPN999096A0 AUPN9990A AUPN999096A AUPN999096A0 AU PN999096 A0 AUPN999096 A0 AU PN999096A0 AU PN9990 A AUPN9990 A AU PN9990A AU PN999096 A AUPN999096 A AU PN999096A AU PN999096 A0 AUPN999096 A0 AU PN999096A0
Authority
AU
Australia
Prior art keywords
vaccines
peptides
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN9990A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHSTAR BIOLOGICALS Pty Ltd
Original Assignee
NORTHSTAR BIOLOG Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHSTAR BIOLOG Pty Ltd filed Critical NORTHSTAR BIOLOG Pty Ltd
Priority to AUPN9990A priority Critical patent/AUPN999096A0/en
Publication of AUPN999096A0 publication Critical patent/AUPN999096A0/en
Priority to JP09541271A priority patent/JP2000512130A/en
Priority to NZ332926A priority patent/NZ332926A/en
Priority to BR9709038-7A priority patent/BR9709038A/en
Priority to EP97921529A priority patent/EP1012171A1/en
Priority to CN97196524A priority patent/CN1226896A/en
Priority to NZ337256A priority patent/NZ337256A/en
Priority to CA002255888A priority patent/CA2255888A1/en
Priority to AU27575/97A priority patent/AU738528B2/en
Priority to PCT/AU1997/000312 priority patent/WO1997044352A1/en
Priority to US09/758,128 priority patent/US20020107187A1/en
Priority to US09/758,426 priority patent/US20020169116A1/en
Priority to US09/758,198 priority patent/US20020187925A1/en
Priority to US09/861,661 priority patent/US20030045676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPN9990A 1996-05-22 1996-05-22 Peptides, antibodies, vaccines & uses thereof Abandoned AUPN999096A0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AUPN9990A AUPN999096A0 (en) 1996-05-22 1996-05-22 Peptides, antibodies, vaccines & uses thereof
PCT/AU1997/000312 WO1997044352A1 (en) 1996-05-22 1997-05-22 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
NZ337256A NZ337256A (en) 1996-05-22 1997-05-22 Pharmaceutical carrier derived from deep sea shark oil and uses thereof
AU27575/97A AU738528B2 (en) 1996-05-22 1997-05-22 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
BR9709038-7A BR9709038A (en) 1996-05-22 1997-05-22 Modulation of the activity of hormones or their receptor-peptides, antibodies, vaccines and their uses
EP97921529A EP1012171A1 (en) 1996-05-22 1997-05-22 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
CN97196524A CN1226896A (en) 1996-05-22 1997-05-22 Modulating activity of hormones or their receptors-peptides, antibodies, vaccines and uses thereof
JP09541271A JP2000512130A (en) 1996-05-22 1997-05-22 Methods for regulating the activity of hormones or their receptors, peptides, antibodies, vaccines and uses thereof
CA002255888A CA2255888A1 (en) 1996-05-22 1997-05-22 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
NZ332926A NZ332926A (en) 1996-05-22 1997-05-22 Immunogenic non-naturally occurring peptides and molecules based on somatostatin that modulate the activity of hormones or their receptors peptides, antibodies, vaccines and uses thereof
US09/758,198 US20020187925A1 (en) 1996-05-22 2001-01-12 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US09/758,128 US20020107187A1 (en) 1996-05-22 2001-01-12 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US09/758,426 US20020169116A1 (en) 1996-05-22 2001-01-12 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US09/861,661 US20030045676A1 (en) 1996-05-22 2001-05-22 Peptides, antibodies, vaccines & uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9990A AUPN999096A0 (en) 1996-05-22 1996-05-22 Peptides, antibodies, vaccines & uses thereof

Publications (1)

Publication Number Publication Date
AUPN999096A0 true AUPN999096A0 (en) 1996-06-13

Family

ID=3794302

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPN9990A Abandoned AUPN999096A0 (en) 1996-05-22 1996-05-22 Peptides, antibodies, vaccines & uses thereof

Country Status (8)

Country Link
EP (1) EP1012171A1 (en)
JP (1) JP2000512130A (en)
CN (1) CN1226896A (en)
AU (1) AUPN999096A0 (en)
BR (1) BR9709038A (en)
CA (1) CA2255888A1 (en)
NZ (1) NZ332926A (en)
WO (1) WO1997044352A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017154A1 (en) * 2001-05-18 2003-01-23 Hunchar Jeffrey G. Method of increasing uniformity in avians
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
FR2874156B1 (en) * 2004-08-13 2007-04-06 Univ Rennes 1 Etablissement Pu FEED SUPPLEMENT FOR ANIMALS AND METHOD OF CARRYING OUT SAID METHOD
WO2006060419A2 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
CN101613409B (en) 2005-06-17 2014-06-04 英克隆有限责任公司 PDGFR-alpha antibody
ES2937113T3 (en) * 2006-01-20 2023-03-24 Starpharma Pty Ltd modified macromolecule
CA2641310C (en) 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
JP5627581B2 (en) * 2008-06-25 2014-11-19 ブラーシュ・バイオテック・エルエルシー Compositions and methods for enhancing somatostatin immunogenicity
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
MX2018015592A (en) 2016-06-14 2019-04-24 Xencor Inc Bispecific checkpoint inhibitor antibodies.
CA3029328A1 (en) * 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH647246A5 (en) * 1981-03-06 1985-01-15 Sandoz Ag Polypeptide derivatives, their preparation and pharmaceutical products which contain these polypeptide derivatives
CH679045A5 (en) * 1987-06-29 1991-12-13 Sandoz Ag
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
JPH0782162A (en) * 1993-09-10 1995-03-28 Pola Chem Ind Inc Dermatic agent for external use

Also Published As

Publication number Publication date
NZ332926A (en) 2000-08-25
BR9709038A (en) 2000-01-04
CA2255888A1 (en) 1997-11-27
CN1226896A (en) 1999-08-25
JP2000512130A (en) 2000-09-19
EP1012171A1 (en) 2000-06-28
WO1997044352A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2958997A (en) Concentrated antibody preparation
AU4781297A (en) Vaccines
AU9623898A (en) Vaccines
AU1951201A (en) Peptide antigens
AU4922497A (en) Interleukin-18-receptor proteins
AU2131195A (en) Prophenins - antibiotic peptides
AUPO026596A0 (en) Viral peptide
AU4967397A (en) Water-soluble peptides
AU6820796A (en) Antigenic preparations
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
AU1110297A (en) Novel dnas, novel polypeptides and novel antibodies
AU4990999A (en) Survivin, and peptides thereof, as an anti-cancer vaccine
AU2539697A (en) Anti-idiotypic antibody vaccines
AU3552797A (en) Vaccine preparations
AU1999999A (en) Contryphan peptides
AU2452301A (en) Protein methylarginine-specific antibodies
AU4843297A (en) Anti-obesity proteins
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof
AUPM489194A0 (en) Peptides
ZA9610510B (en) Novel peptides, the preparation and use thereof.
AU6075498A (en) Vaccines
AU5802898A (en) Anti-obesity proteins
AU5406098A (en) Antigenic peptides reacting with anti-ovary antibodies
AU6001499A (en) Tumor-specific antigen peptides